Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Summit Therapeutics Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $92.93, while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Summit Therapeutics Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | SMMT | |
|---|---|---|
52-Week High | $97.99 | $26.98 |
52-Week Low | $92.76 | $12.55 |
Market Cap | — | $12.06B |
Sector | — | Health |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF (iShares 7-10 Year Treasury Bond ETF) trades at $92.96 with a modest 0.22% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. Recent institutional activity includes Bank of America increasing its position by 69.8% in Q2 2026. The ETF continues regular dividend distributions, with the latest payment of $0.32 per share in early August 2026.
The outlook for IEF remains challenged by rising Treasury yields and inflation concerns, with technical weakness suggesting continued pressure. However, institutional accumulation and consistent dividend payments provide some support. Key risks include Federal Reserve rate policy uncertainty and Middle East geopolitical tensions impacting oil prices and inflation expectations.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
